Gemma Iserte
Overview
Explore the profile of Gemma Iserte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Granel N, Iserte G, Bartres C, Llarch N, Pla A, Sapena V, et al.
BMC Gastroenterol
. 2025 Feb;
25(1):51.
PMID: 39901067
Background: The eradication of the Hepatitis C Virus (HCV) reduce the risk of liver cancer (LC), but lifestyle changes after cure may counterbalance its benefit. Our study investigates lifestyle changes...
2.
Ros-Buxo M, Mauro E, Sauri T, Iserte G, Fuster-Anglada C, Diaz A, et al.
Curr Oncol
. 2024 Jul;
31(7):3615-3629.
PMID: 39057138
Biliary tract cancers (BTCs) are rare and aggressive malignancies with an increasing incidence and poor prognosis. The standard systemic treatment for BTCs has evolved to include immune checkpoint inhibitors associated...
3.
Mauro E, Sanduzzi-Zamparelli M, Sauri T, Soler A, Iserte G, Fortuny M, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893196
Background: For biliary tract cancer (BTC), the addition of immunotherapy (durvalumab or pembrolizumab) to gemcitabine and cisplatin (GemCis) significantly improved overall survival (OS) in phase 3 clinical trials (RCTs). However,...
4.
Munoz-Martinez S, Sapena V, Garcia-Criado A, Darnell A, Forner A, Belmonte E, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444380
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the...
5.
Mauro E, Ferrer-Fabrega J, Sauri T, Soler A, Cobo A, Burrel M, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831586
Cholangiocarcinoma (CCA) is a neoplasm with high mortality that represents 15% of all primary liver tumors. Its worldwide incidence is on the rise, and despite important advances in the knowledge...
6.
El Hajra I, Sanduzzi-Zamparelli M, Sapena V, Munoz-Martinez S, Mauro E, Llarch N, et al.
Hepatology
. 2023 Jan;
77(4):1139-1149.
PMID: 36632997
Background And Aims: Immunotherapy-based regimes have changed the management of HCC. However, evidence of efficacy in patients with impaired liver function is unknown. This systematic review and meta-analysis assesses survival...
7.
Sanduzzi-Zamparelli M, Marino Z, Lens S, Sapena V, Iserte G, Pla A, et al.
J Hepatol
. 2021 Dec;
76(4):874-882.
PMID: 34856322
Background & Aims: Recognition of non-characterized liver nodules (NCLN) prior to direct-acting antivirals (DAAs) is associated with increased hepatocellular carcinoma (HCC) risk in patients with HCV. The risk of HCC...
8.
Munoz-Martinez S, Iserte G, Sanduzzi-Zamparelli M, Llarch N, Reig M
Curr Opin Pharmacol
. 2021 Aug;
60:141-148.
PMID: 34418875
The landscape of hepatocellular carcinoma (HCC) has changed since the incorporation of sorafenib in 2007 as the first pharmacological treatment for HCC. The combination of atezolizumab plus bevacizumab is currently...
9.
Diaz-Gonzalez A, Sapena V, Boix L, Torres F, Sanduzzi-Zamparelli M, da Fonseca L, et al.
United European Gastroenterol J
. 2021 Jul;
9(6):655-661.
PMID: 34228394
Background: Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting...
10.
Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millan C, Samper E, Llarch N, et al.
Cancers (Basel)
. 2021 Jan;
13(3).
PMID: 33498698
Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant...